<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234480</url>
  </required_header>
  <id_info>
    <org_study_id>TPO-10-06084</org_study_id>
    <nct_id>NCT01234480</nct_id>
  </id_info>
  <brief_title>Intended Use Study of the BD SurePath Plus™ Pap</brief_title>
  <official_title>Intended Use Study of the BD SurePath Plus™ Pap</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Becton, Dickinson and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide data on the performance of the BD SurePath Plus™ Pap test for&#xD;
      identifying high grade cervical disease. This study will be conducted with approximately&#xD;
      12,500 women undergoing routine cervical cancer screening, of whom women with abnormal&#xD;
      cytology and/or positive HPV test will be selected to undergo colposcopy and biopsy/ECC.&#xD;
      Subjects with abnormal cytology results with biopsy results of less than or equal to CIN1 or&#xD;
      CIN2 untreated will be asked to return in 6-8 months for follow-up testing. Subjects may be&#xD;
      asked to proceed to a longer-term follow-up study and undergo cytological evaluation annually&#xD;
      for 3 years (separate study).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pivotal, multi-center in vitro diagnostic study comparing the BD SurePath Plus Pap&#xD;
      test to current practice (cytologic examination utilizing the BD SurePath liquid-based Pap&#xD;
      test with conjunctive HPV testing) for the detection of cervical cancer and high-grade&#xD;
      cervical disease (collectively referred to as CIN2+) in women.&#xD;
&#xD;
      The new BD SurePath Plus Pap Test combines a traditional Papanicolaou staining for cellular&#xD;
      morphology, with brown nuclear immunostaining resulting from the over-expression of specific&#xD;
      protein biomarkers, on one slide, to improve the detection of high-grade cervical disease and&#xD;
      cervical cancer (collectively referred to as CIN2+).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Decided not to pursue commercialization of the product&#xD;
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity, Specificity, PPV, and NPV of BD SurePath Plus Pap Test for the Determination of Cervical Disease as Defined by CIN2 or Higher</measure>
    <time_frame>10 months</time_frame>
    <description>Estimate the sensitivity, specificity, positive predictive value and negative predictive value of the BD SurePath Plus Pap test in detecting cervical disease as defined as CIN2 or higher</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the Sensitivity and Specificity of the BD SurePath Plus Pap Test to the SurePath Pap With HPV Reflex Testing for CIN2+ Disease Detection.</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5859</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Uterine Cervical Cancer</condition>
  <condition>Neoplasms, Squamous Cell</condition>
  <condition>Neoplasms, Glandular and Epithelial</condition>
  <condition>Neoplasms by Histologic Type</condition>
  <condition>Neoplasms</condition>
  <condition>Papilloma</condition>
  <arm_group>
    <arm_group_label>Participants with Cervical Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants positive for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants without Cervical Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants negative for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BD SurePath Plus Pap test</intervention_name>
    <description>BD SurePath Plus Pap test</description>
    <arm_group_label>Participants with Cervical Disease</arm_group_label>
    <arm_group_label>Participants without Cervical Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BD SurePath Pap test</intervention_name>
    <description>BD SurePath Plus Pap test</description>
    <arm_group_label>Participants with Cervical Disease</arm_group_label>
    <arm_group_label>Participants without Cervical Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colposcopy with biopsy/ECC</intervention_name>
    <description>Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher</description>
    <arm_group_label>Participants with Cervical Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HPV DNA test</intervention_name>
    <description>digene HC2 HPV DNA test</description>
    <arm_group_label>Participants with Cervical Disease</arm_group_label>
    <arm_group_label>Participants without Cervical Disease</arm_group_label>
    <other_name>digene HC2 HPV DNA test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Study subjects must give voluntary written informed consent to participate in this study.&#xD;
&#xD;
        - Females ages 18 - 35 years, inclusive; or women at high- risk for cervical cancer or its&#xD;
        precursor lesions.&#xD;
&#xD;
        High-risk is defined as:&#xD;
&#xD;
          -  Have had a previous high-risk HPV positive test in the last 5 years; or&#xD;
&#xD;
          -  Have had an abnormal Pap test (ASC-US or higher) in the last 5 years; or&#xD;
&#xD;
          -  Have not been screened for cervical cancer by either a Pap test or HPV test in the&#xD;
             last 5 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are 36 years of age or greater who are not high risk, and/or:&#xD;
&#xD;
               1. Have not had an abnormal Pap in the last 5 years; or&#xD;
&#xD;
               2. Have not had a positive HPV test in the last 5 years; or&#xD;
&#xD;
               3. Have been screened in the last 5 years without an abnormal Pap or HPV result&#xD;
&#xD;
          -  Subjects known to be pregnant or planning to become pregnant prior to the potential&#xD;
             six months follow-up visit (self-reported). Subjects who decide to become pregnant&#xD;
             prior to the six-month follow up visit or found to be pregnant after the first visit,&#xD;
             but prior to the six-month follow-up visit will be terminated from further study&#xD;
             participation at that time&#xD;
&#xD;
          -  Subjects who have had a prior complete or partial hysterectomy involving removal of&#xD;
             the cervix.&#xD;
&#xD;
          -  Subjects who have had an application of chemical compounds to the cervical area within&#xD;
             the 24 hours prior to study entry, e.g., acetic acid, iodine, spermicide, douche,&#xD;
             anti-fungal medications, etc.&#xD;
&#xD;
          -  Subjects on whom conization, LEEP, laser surgery, or cryosurgery has been performed&#xD;
             within the past five months.&#xD;
&#xD;
          -  Subjects currently undergoing radiation and/or chemotherapy.&#xD;
&#xD;
          -  Subjects under the age of 18.&#xD;
&#xD;
          -  Subjects who have previously received a HPV vaccine with any number of doses.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seattle Women's: Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <results_first_submitted>April 12, 2021</results_first_submitted>
  <results_first_submitted_qc>April 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2021</results_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liquid based cytology</keyword>
  <keyword>Surepath</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>All Enrolled Participants - Cervical cancer status was not known upon enrollment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5859"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5416"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="443"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>&gt;36/Normal History</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Age</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HPV Vaccine History</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HPV Vaccine after Enrollment</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hysterectomy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hysterectomy post enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Informed Consent Form Violation</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect Visit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Florida Lab License</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Out of Window</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sample Processing/Storage</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Amendment prohibited colposcopy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site/Subject non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing Sample</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants with evaluable samples.</population>
      <group_list>
        <group group_id="B1">
          <title>All Evaluable Participants</title>
          <description>All participants with satisfactory samples at completion of the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3731"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3731"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="889"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2842"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity, Specificity, PPV, and NPV of BD SurePath Plus Pap Test for the Determination of Cervical Disease as Defined by CIN2 or Higher</title>
        <description>Estimate the sensitivity, specificity, positive predictive value and negative predictive value of the BD SurePath Plus Pap test in detecting cervical disease as defined as CIN2 or higher</description>
        <time_frame>10 months</time_frame>
        <population>All evaluable non-missing samples.</population>
        <group_list>
          <group group_id="O1">
            <title>SurePath Plus</title>
            <description>Samples tested on the SurePath Plus</description>
          </group>
          <group group_id="O2">
            <title>SurePath Pap</title>
            <description>Samples tested on the SurePath Pap</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity, Specificity, PPV, and NPV of BD SurePath Plus Pap Test for the Determination of Cervical Disease as Defined by CIN2 or Higher</title>
          <description>Estimate the sensitivity, specificity, positive predictive value and negative predictive value of the BD SurePath Plus Pap test in detecting cervical disease as defined as CIN2 or higher</description>
          <population>All evaluable non-missing samples.</population>
          <units>Percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3731"/>
                <count group_id="O2" value="3731"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity (ASC-US+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" lower_limit="77.4" upper_limit="90.2"/>
                    <measurement group_id="O2" value="71.4" lower_limit="62.7" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity (ASC-US+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="83.5" upper_limit="85.9"/>
                    <measurement group_id="O2" value="88.7" lower_limit="87.5" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPV (ASC-US+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="15.1" upper_limit="18.2"/>
                    <measurement group_id="O2" value="18.5" lower_limit="16.2" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NPV (ASC-US+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="99.0" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.9" lower_limit="98.5" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitivity (ASC-H+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" lower_limit="56.6" upper_limit="73.5"/>
                    <measurement group_id="O2" value="43.7" lower_limit="35.1" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity (ASC-H+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" lower_limit="91.2" upper_limit="93.1"/>
                    <measurement group_id="O2" value="94.4" lower_limit="93.5" upper_limit="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPV (ASC-H+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="20.1" upper_limit="26.3"/>
                    <measurement group_id="O2" value="21.8" lower_limit="17.8" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NPV (ASC-H+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="98.3" upper_limit="99.0"/>
                    <measurement group_id="O2" value="97.9" lower_limit="97.6" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitivity (LSIL+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0" lower_limit="49.0" upper_limit="66.5"/>
                    <measurement group_id="O2" value="40.3" lower_limit="32.0" upper_limit="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity (LSIL+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="92.5" upper_limit="94.2"/>
                    <measurement group_id="O2" value="94.7" lower_limit="93.8" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPV (LSIL+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="20.4" upper_limit="27.6"/>
                    <measurement group_id="O2" value="21.4" lower_limit="17.2" upper_limit="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NPV (LSIL+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="98.1" upper_limit="98.7"/>
                    <measurement group_id="O2" value="97.8" lower_limit="97.5" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitivity (HSIL+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" lower_limit="29.6" upper_limit="46.8"/>
                    <measurement group_id="O2" value="16.0" lower_limit="10.5" upper_limit="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity (HSIL+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="97.8" upper_limit="98.7"/>
                    <measurement group_id="O2" value="99.8" lower_limit="99.6" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPV (HSIL+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" lower_limit="36.5" upper_limit="53.3"/>
                    <measurement group_id="O2" value="76.0" lower_limit="56.9" upper_limit="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NPV (HSIL+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="97.5" upper_limit="98.1"/>
                    <measurement group_id="O2" value="97.1" lower_limit="96.9" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare the Sensitivity and Specificity of the BD SurePath Plus Pap Test to the SurePath Pap With HPV Reflex Testing for CIN2+ Disease Detection.</title>
        <time_frame>10 months</time_frame>
        <population>Evaluable samples that had also had HPV reflex testing</population>
        <group_list>
          <group group_id="O1">
            <title>SurePath Plus With Immunostain</title>
            <description>Samples tested on the SurePath Plus</description>
          </group>
          <group group_id="O2">
            <title>SurePath Pap With HPV</title>
            <description>Samples tested on the SurePath Pap</description>
          </group>
        </group_list>
        <measure>
          <title>Compare the Sensitivity and Specificity of the BD SurePath Plus Pap Test to the SurePath Pap With HPV Reflex Testing for CIN2+ Disease Detection.</title>
          <population>Evaluable samples that had also had HPV reflex testing</population>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity (ASC-US)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" lower_limit="62.2" upper_limit="89.3"/>
                    <measurement group_id="O2" value="87.9" lower_limit="72.7" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity (ASC-US)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" lower_limit="38.8" upper_limit="52.9"/>
                    <measurement group_id="O2" value="41.5" lower_limit="34.7" upper_limit="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Evaluable Participants</title>
          <description>All participants with satisfactory samples at completion of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3731"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3731"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3731"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Yanson</name_or_title>
      <organization>Becton Dickinson</organization>
      <phone>410-316-4793</phone>
      <email>karen_a_yanson@bd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

